C. Boyd Clarke Net Worth

The estimated Net Worth of C. Boyd Clarke is at least $95.9 millier dollars as of 6 August 2014. C Clarke owns over 3,000 units of Aldeyra Therapeutics Inc stock worth over $95,945 and over the last 11 years C sold ALDX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

C Clarke ALDX stock SEC Form 4 insiders trading

C has made over 2 trades of the Aldeyra Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently C bought 3,000 units of ALDX stock worth $11,070 on 6 August 2014.

The largest trade C's ever made was buying 12,500 units of Aldeyra Therapeutics Inc stock on 7 May 2014 worth over $100,000. On average, C trades about 3,875 units every 23 days since 2014. As of 6 August 2014 C still owns at least 15,500 units of Aldeyra Therapeutics Inc stock.

You can see the complete history of C Clarke stock trades at the bottom of the page.

What's C Clarke's mailing address?

C's mailing address filed with the SEC is C/O ALDEYRA THERAPEUTICS, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON, MA, 01803.

Insiders trading at Aldeyra Therapeutics Inc

Over the last 11 years, insiders at Aldeyra Therapeutics Inc have traded over $6,285,725 worth of Aldeyra Therapeutics Inc stock and bought 11,547,153 units worth $75,179,936 . The most active insiders traders include Advisors Llcperceptive Life..., & Johnson Johnson & Johnson... et Advisors Llcedelman Josephp.... On average, Aldeyra Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $1,358,662. The most recent stock trade was executed by Stephen Machatha on 12 August 2024, trading 16,041 units of ALDX stock currently worth $76,034.

What does Aldeyra Therapeutics Inc do?

dedicated to improving lives by developing products that treat aldehyde-mediated diseases. we are a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes. we are developing adx-102 (formerly ns2), as well as other novel product candidates that are designed specifically to sequester aldehydes, for the treatment of: • noninfectious anterior uveitis, a rare severe inflammatory eye disease that can lead to blindness; • allergic conjunctivitis, a common disease that affects more than 20% of the population worldwide, and related rare allergic ocular diseases that are characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in ocular itching, excessive tear production, swelling, and redness; • dry eye disease, a common inflammatory dise

Complete history of C Clarke stock trades at Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc executives and stock owners

Aldeyra Therapeutics Inc executives and other stock owners filed with the SEC include:

• Todd Brady,
  President, Chief Executive Officer, Director
• Joshua Reed,
  Chief Financial Officer
• David McMullin,
  Chief Commercial Officer
• Dr. Todd C. Brady M.D., Ph.D.,
  CEO, Pres & Director
• Joshua Reed M.B.A.,
  Chief Financial Officer
• Richard Douglas,
  Independent Chairman of the Board
• Martin Joyce,
  Independent Director
• Jesse Treu,
  Independent Director
• Ben Bronstein,
  Independent Director
• Gary Phillips,
  Independent Director
• Neal Walker,
  Independent Director
• Scott Solomon,
  IR Contact Officer
• Nancy Miller-rich,
  Independent Director
• Stephen Machatha,
  Senior Vice President, Technical Operations
• James Gow,
  Senior Vice President - Clinical Development
• Bruce Greenberg CPA, M.B.A.,
  VP & Controller
• Dr. Stephen G. Machatha Ph.D.,
  Chief Devel. Officer
• Kelly Mizer,
  VP of Commercial Strategy & Operations
• David J Clark,
  Chief Medical Officer
• Advisors Llcedelman Josephp...,
  
• C. Boyd Clarke,
  Director
• Stephen J Tulipano,
  Chief Financial Officer
• Scott Young,
  Chief Operating Officer
• Bruce Greenberg,
  See Remarks
• Advisors Llcperceptive Life...,
  
• Partners Vi, L.P.Blair Jame...,
  
• & Johnson Johnson & Johnson...,
  
• Vi Associates, L.P.Blair Ja...,